Mary is the associate editorial director for The American Journal of Managed Care® (AJMC®), The Center for Biosimilars®, and Evidence-Based Oncology™. She joined AJMC® in 2013 and oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®.
She has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn or Twitter.
Dr Judy Wang on the Potential of CLN-619 for the Treatment of Solid TumorsJune 5th 2023
Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.
Dr Bhagirathbhai Dholaria Discusses TRiMM-2 Trial FindingsJune 4th 2023
Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.
Nivolumab Cuts Risk of Disease Progression or Death by 52% in Untreated Hodgkin Lymphoma Compared With Brentuximab VedotinJune 4th 2023
The landmark trial harmonized treatment between adult and pediatric patients with classic Hodgkin lymphoma, who historically have received different chemotherapy regimens; young patients have received more treatment with radiation.
Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer StudiesJune 3rd 2023
Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
ASCO 2023 to Highlight Treatment Options, Partnerships With Patients in Guiding Cancer CareMay 30th 2023
The cancer care community descends on Chicago this weekend for the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). This year’s theme, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” highlights how recent advances make interactions between clinicians and patients more important than ever, as shared decision-making must be the foundation of the care journey.
Dr Andrew Evens on the SWOG S1826 Trial and Changing Landscape of Hodgkin LymphomaMay 30th 2023
Andrew Evens, DO, MBA, MSc, associate director for clinical services at Rutgers Cancer Institute, discussed the ways in which SWOG S1826 trial results will build on current knowledge of Hodgkin lymphoma treatment.
QCCA Session Explores Making Service Delivery EfficientMay 15th 2023
A panel of top practice administrators, moderated by Danielle Geiger, APRN-NP, of Nebraska Cancer Specialists, explored ways for practices to improve the bottom line at the Quality Cancer Care Alliance (QCCA) spring conference, held April 19-21, 2023.
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?May 6th 2023
For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
TPG, AmerisourceBergen Acquire OneOncology in Deal Valued at $2.1 BillionApril 20th 2023
Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.
As More Survive Cancer, Issues With Sleep, Fatigue, Cognitive Function on the RiseApril 15th 2023
The April 2 plenary session at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference, entitled, “Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors" reviewed guidelines for handling symptoms that are increasingly common as the survivorship ranks grow.
NCCN Session Offers Considerations for Frontline, Second-line Treatment Choices in CLLApril 12th 2023
An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.
Early Recognition Key to Management of Immunotherapy ToxicitiesApril 11th 2023
As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.
Characteristics of Relapse Affect Treatment Choices in Multiple MyelomaApril 3rd 2023
Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.